MedPath

Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy

Not Applicable
Withdrawn
Conditions
COVID-19
Registration Number
NCT05069636
Lead Sponsor
Rowan University
Brief Summary

The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine.
Exclusion Criteria
  • Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levelsThe day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose

Antibody levels collected via blood draw

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rowan University School of Osteopathic Medicine

🇺🇸

Stratford, New Jersey, United States

Rowan University School of Osteopathic Medicine
🇺🇸Stratford, New Jersey, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.